In the present study, all Lunx-positive patients with MPEs were diagnosed with pulmonary carcinoma, and all extrapulmonary carcinoma patients were Lunx-negative. From the above results, we conclude that if the Lunx mRNA https://www.selleckchem.com/products/necrostatin-1.html expression in a patient with MPE is positive, then the source of the tumor cells should be the lungs. Lunx mRNA is an effective marker of pulmonary carcinoma. In the present study, we analyzed the
relationship between Lunx mRNA expression and clinical parameters. We found no association between the levels of Lunx mRNA expression and LDH levels, glucose levels, albumin in the pleural effusion, PH, or histopathological category. However, there were significantly increased levels of Lunx mRNA expression in poorly differentiated tumors compared to moderately and well differentiated Apoptosis inhibitor tumors. The degree of tumor cell differentiation is recognized as one index to evaluate prognosis. We presume that Lunx mRNA expression levels may be associated with the prognosis of patients with MPE caused by pulmonary carcinoma. Once diagnosed, chemotherapy
is the main method to treat patients with MPE caused by pulmonary carcinoma [16]. In the CR and PR groups, we found that the expression of Lunx mRNA was significantly decreased after the first session of chemotherapy. There was no significant difference Osimertinib in the NC group; however, the expression of Lunx mRNA significantly increased in the PD group. These data indicate that the change in Lunx mRNA expression
may be associated with the patients’ response to chemotherapy and that Lunx mRNA expression is an effective index for evaluating the Exoribonuclease effect of chemotherapy. To investigate this idea further, we divided the patients who accepted chemotherapy into two groups according the change in direction of Lunx mRNA expression, and investigated the overall survival of the patients. We found that the patients in the increased Lunx mRNA expression group had longer overall survival times than those in the decreased Lunx mRNA expression group. These data indicated that the change in direction of Lunx mRNA expression after chemotherapy can predict the prognosis of patients. Conclusions In conclusion, Lunx mRNA is a specific tumor gene that is highly expressed in MPE caused by pulmonary carcinoma. The detection of Lunx mRNA before and after chemotherapy can help clinicians predict the prognosis of patients. Lunx mRNA is a sensitive marker for distinguishing MPEs caused by pulmonary carcinoma from pleural effusions caused by other reasons. This detection may lead to the early diagnosis of patients with MPE caused by pulmonary carcinoma. Acknowledgements This work was supported by the Science and Technology Department of Jilin Province, China (No. 20110489). References 1. Heffner JE, Klein JS: Recent Advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc 2008, 83:235–250.PubMed 2.